Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma

J. Tóth, Kristof Egervari, A. Klekner, L. Bognár, J. Szántó, Z. Nemes, Zoltan Szollosi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15-20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.

Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalPathology and Oncology Research
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 2009

Fingerprint

erbB-1 Genes
Gene Amplification
Glioblastoma
Protein-Tyrosine Kinases
Phosphotransferases
Mutation
Proteins
Protein Kinases
Lung Neoplasms
Clinical Trials
Neoplasms
epidermal growth factor receptor VIII

Keywords

  • EGFR
  • Glioblastoma multiforme
  • Kinase inhibitor treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{919690e8ac6c42a6bfb3d7bad62c797b,
title = "Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma",
abstract = "Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15-20{\%} of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65{\%} of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35{\%} of cases, and with high polysomy in 15{\%} of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.",
keywords = "EGFR, Glioblastoma multiforme, Kinase inhibitor treatment",
author = "J. T{\'o}th and Kristof Egervari and A. Klekner and L. Bogn{\'a}r and J. Sz{\'a}nt{\'o} and Z. Nemes and Zoltan Szollosi",
year = "2009",
month = "6",
doi = "10.1007/s12253-008-9082-4",
language = "English",
volume = "15",
pages = "225--229",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma

AU - Tóth, J.

AU - Egervari, Kristof

AU - Klekner, A.

AU - Bognár, L.

AU - Szántó, J.

AU - Nemes, Z.

AU - Szollosi, Zoltan

PY - 2009/6

Y1 - 2009/6

N2 - Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15-20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.

AB - Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15-20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.

KW - EGFR

KW - Glioblastoma multiforme

KW - Kinase inhibitor treatment

UR - http://www.scopus.com/inward/record.url?scp=68949110285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949110285&partnerID=8YFLogxK

U2 - 10.1007/s12253-008-9082-4

DO - 10.1007/s12253-008-9082-4

M3 - Article

VL - 15

SP - 225

EP - 229

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -